Although numerous topical and systemic therapeutic agents and also non-pharmacologic procedural treatments have been considered in melasma management, however, the commonly available therapeutic options have several limitations including the lack of sufficient clinical effectiveness, risk of relapse, and high rate of unwanted adverse drug reactions
The table below summarizes the percentage reduction in total fat mass from baseline at week 36: The 8mg dose produced the highest fat mass reduction at 26.1%, which represents an exceptional result in obesity pharmacotherapy
Evening Injections : Some patients prefer evening shots to sleep through side effects
While some existing studies have explored discontinuation rates, theyve identified widely varying rates of GLP-1 RA discontinuation at one year and factors such as cost, insurance, comorbidities and absence of type 2 diabetes (T2D) have been associated with that discontinuation
The full scope at Ascend includes: Obesity and overweight with comorbidities - full workup, GLP-1 candidacy assessment, lifestyle integration Type 2 diabetes with weight management goals - GLP-1 medications often address both indications simultaneously Hypertension tied to weight - coordinated medication review and lifestyle work Dyslipidemia and metabolic syndrome - lipids often improve markedly with weight loss Prediabetes - HbA1c 5.7-6.4% range, where intervention can prevent progression Fatty liver disease (MASLD) - weight loss is the primary intervention
Rashes such as eczema and hives can be due to an allergic reaction